PMC:7074432 / 1780-2391
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
96 | 0-13 | Gene | denotes | Neuraminidase | Gene:4758 |
97 | 97-105 | Species | denotes | MERS-CoV | Tax:1335626 |
98 | 154-162 | Species | denotes | patients | Tax:9606 |
99 | 196-204 | Species | denotes | patients | Tax:9606 |
100 | 218-233 | Species | denotes | influenza virus | Tax:11309 |
101 | 354-362 | Species | denotes | MERS-CoV | Tax:1335626 |
102 | 423-431 | Species | denotes | MERS-CoV | Tax:1335626 |
103 | 484-493 | Species | denotes | 2019-nCoV | Tax:2697049 |
104 | 60-69 | Species | denotes | influenza | Tax:11309 |
105 | 172-183 | Chemical | denotes | oseltamivir | MESH:D053139 |
106 | 266-277 | Chemical | denotes | oseltamivir | MESH:D053139 |
107 | 314-325 | Chemical | denotes | oseltamivir | MESH:D053139 |
108 | 408-419 | Chemical | denotes | oseltamivir | MESH:D053139 |
109 | 437-448 | Chemical | denotes | Oseltamivir | MESH:D053139 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T107 | 14-24 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T106 | 97-105 | SP_9 | denotes | MERS-CoV |
T105 | 172-183 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T104 | 218-227 | NCBITaxon:7719 | denotes | influenza |
T103 | 228-233 | NCBITaxon:10239 | denotes | virus |
T102 | 266-277 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T101 | 314-325 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T100 | 354-362 | SP_9 | denotes | MERS-CoV |
T99 | 408-419 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T98 | 423-431 | SP_9 | denotes | MERS-CoV |
T97 | 437-448 | CHEBI:7798;CHEBI:7798 | denotes | Oseltamivir |
T96 | 484-493 | SP_7 | denotes | 2019-nCoV |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T13 | 60-69 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T14 | 218-227 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T8 | 77-78 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T9 | 140-141 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 151-153 | http://purl.obolibrary.org/obo/CLO_0001000 | denotes | 35 |
T11 | 228-233 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T12 | 244-246 | http://purl.obolibrary.org/obo/CLO_0001407 | denotes | 52 |
T13 | 433-435 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T16 | 0-24 | Chemical | denotes | Neuraminidase inhibitors | http://purl.obolibrary.org/obo/CHEBI_52425 |
T17 | 14-24 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T18 | 172-183 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T19 | 266-277 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T20 | 314-325 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T21 | 408-419 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T22 | 437-448 | Chemical | denotes | Oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T23 | 586-591 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T15 | 0-192 | Sentence | denotes | Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). |
T16 | 193-611 | Sentence | denotes | In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12] |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32201439-30012113-47219407 | 370-372 | 30012113 | denotes | 10 |
32201439-30882305-47219408 | 433-435 | 30882305 | denotes | 11 |
32201439-31986264-47219409 | 608-610 | 31986264 | denotes | 12 |
T19064 | 370-372 | 30012113 | denotes | 10 |
T33497 | 433-435 | 30882305 | denotes | 11 |
T42850 | 608-610 | 31986264 | denotes | 12 |